Cisen Pharmaceutical Co Ltd Working Capital to Net Assets Ratio
Cisen Pharmaceutical Co Ltd working capital to net assets ratio. Cisen Pharmaceutical Co Ltd (603367) has a Working Capital to Net Assets ratio of 70.2% as of June 2026. Working capital of CN¥4.51 Billion (current assets of CN¥5.79 Billion minus current liabilities of CN¥1.28 Billion) is measured against net assets of CN¥6.42 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check Cisen Pharmaceutical Co Ltd tangible net worth ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Cisen Pharmaceutical Co Ltd (2011–2025)
Working capital to net assets ratio of Cisen Pharmaceutical Co Ltd from 2011 to 2025. This chart shows how Cisen Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 15 annual periods from 2011 to 2025. As of June 2026, the ratio stands at 70.2%, reflecting working capital of CN¥4.51 Billion against net assets of CN¥6.42 Billion CNY. See Cisen Pharmaceutical Co Ltd defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Cisen Pharmaceutical Co Ltd Working Capital to Net Assets Ratio by Year (2011–2025)
Cisen Pharmaceutical Co Ltd working capital to net assets ratio by year from 2011 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Cisen Pharmaceutical Co Ltd from 2011 to 2025, covering 15 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Cisen Pharmaceutical Co Ltd balance sheet assets.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 64.0% | CN¥3.99 Billion | CN¥6.23 Billion | CN¥5.21 Billion | CN¥1.22 Billion | ▲ +6.0 pp |
| 2024 | 58.0% | CN¥3.47 Billion | CN¥5.99 Billion | CN¥4.96 Billion | CN¥1.49 Billion | ▼ -4.4 pp |
| 2023 | 62.4% | CN¥3.60 Billion | CN¥5.77 Billion | CN¥4.97 Billion | CN¥1.37 Billion | ▼ -2.2 pp |
| 2022 | 64.7% | CN¥3.46 Billion | CN¥5.36 Billion | CN¥4.74 Billion | CN¥1.28 Billion | ▲ +6.8 pp |
| 2021 | 57.9% | CN¥2.93 Billion | CN¥5.06 Billion | CN¥4.14 Billion | CN¥1.22 Billion | ▲ +2.4 pp |
| 2020 | 55.5% | CN¥2.67 Billion | CN¥4.80 Billion | CN¥3.95 Billion | CN¥1.28 Billion | ▼ -7.8 pp |
| 2019 | 63.3% | CN¥2.90 Billion | CN¥4.57 Billion | CN¥3.78 Billion | CN¥885.54 Million | ▲ +1.1 pp |
| 2018 | 62.3% | CN¥2.59 Billion | CN¥4.15 Billion | CN¥3.60 Billion | CN¥1.01 Billion | ▲ +4.1 pp |
| 2017 | 58.2% | CN¥2.17 Billion | CN¥3.72 Billion | CN¥3.09 Billion | CN¥918.88 Million | ▲ +25.0 pp |
| 2016 | 33.1% | CN¥761.57 Million | CN¥2.30 Billion | CN¥1.50 Billion | CN¥735.54 Million | ▲ +18.2 pp |
| 2015 | 14.9% | CN¥313.16 Million | CN¥2.10 Billion | CN¥1.16 Billion | CN¥851.02 Million | ▲ +9.5 pp |
| 2014 | 5.4% | CN¥103.37 Million | CN¥1.90 Billion | CN¥806.45 Million | CN¥703.07 Million | ▼ -11.8 pp |
| 2013 | 17.3% | CN¥297.96 Million | CN¥1.73 Billion | CN¥856.77 Million | CN¥558.81 Million | ▼ -17.8 pp |
| 2012 | 35.1% | CN¥555.61 Million | CN¥1.58 Billion | CN¥1.01 Billion | CN¥452.88 Million | ▼ -6.0 pp |
| 2011 | 41.0% | CN¥551.42 Million | CN¥1.34 Billion | CN¥777.44 Million | CN¥226.02 Million | — |